Comprehensive Smartwatch Reference Platform to
Include Key Hardware and Software Components, Including
Industry-leading Masimo Biosensing Capabilities
Masimo (NASDAQ: MASI), a leading global medical innovator, today
announced a partnership with Google to develop a new reference
platform for original equipment manufacturers (OEMs) building Wear
OS by Google™ smartwatches. By incorporating Masimo’s breakthrough
biosensing technologies – based on its decades of expertise
developing industry-leading hospital monitoring solutions – and
standardizing smartwatch devices using the Masimo reference
platform, OEMs will be able to more efficiently build and bring
high-performing Wear OS smartwatches to market. The robust
reference platform is designed to support the fast-growing Wear OS
ecosystem – including with a suite of health and wellness tracking
tools that consumers can trust to provide accurate, reliable data,
seamless integration with Android™ smartphones, and a high-quality,
high-performance experience.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240913710494/en/
Masimo and Wear OS by Google (Graphic:
Business Wire)
Joe Kiani, Founder and CEO of Masimo, said, “We’re excited to
partner with Google to develop a reference platform for Wear OS
that leverages our expert engineering capabilities. Our ability to
craft next generation biosensing technologies, precision
components, and advanced signal processing algorithms, with rigor
and discipline honed over decades, is an excellent foundation for
creating a world-class smartwatch reference platform. From hardware
to software, Masimo engineers are optimizing the ‘guts’ of the
smartwatch – and working with Google to offer OEMs an incredible
Wear OS smartwatch solution. Much as numerous leading hospital
monitor manufacturers incorporate Masimo monitoring technologies to
offer hospitals the best possible patient monitoring solutions, we
expect this new wearable platform to supercharge smartwatch OEMs’
abilities to create innovative, competitive, and truly compelling
Wear OS smartwatches for consumers everywhere.”
Bjorn Kilburn, GM of Wear OS at Google, added, “Building quality
smartwatches with premium features that users have come to expect
can be time consuming and costly. With Masimo's reference platform,
smartwatch makers are able to benefit from state-of-the-art
biosensing technology and quickly bring their Wear OS devices to
market, at scale. Together, we're promoting innovation across the
Wear OS ecosystem that provides end users with high-performing,
feature-rich devices to choose from.”
OEMs who adopt the new Masimo platform, which is expected to be
compatible with existing Google apps and services created for the
Wear OS platform, will continue to design and produce their new
smartwatches’ physical exteriors and have creative control over the
appearance of the user interface. The devices’ interiors, including
optimized hardware and software components, biosensors, and
companion Android smartphone app, will be designed, provided, and
tested by Masimo – ensuring superior performance and unmatched user
experiences. Health and wellness capabilities will feature the same
biosensing innovations and analytics that power the Masimo W1®
wearable and forthcoming Masimo Freedom™ smartwatch – technology
based on Masimo’s clinically proven, industry-leading Signal
Extraction Technology® (SET®). The Masimo reference platform will
make all of these components, features, and benefits available for
smartwatch manufacturers building Wear OS smartwatches in an
easy-to-implement, standardized package.
Google, Android and Wear OS by Google are trademarks of Google
LLC.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. In addition, Masimo Consumer Audio is home to eight
legendary audio brands, including Bowers & Wilkins, Denon,
Marantz, and Polk Audio. Our mission is to improve life, improve
patient outcomes, and reduce the cost of care. Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
introduced in 1995, has been shown in over 100 independent and
objective studies to outperform other pulse oximetry technologies.1
Masimo SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,2 improve CCHD screening in
newborns,3 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
team activations, ICU transfers, and costs.4-5 Masimo SET® is
estimated to be used on more than 200 million patients in leading
hospitals and other healthcare settings around the world,6 and is
the primary pulse oximetry at all 10 top U.S. hospitals as ranked
in the 2024 Newsweek World’s Best Hospitals listing.7 In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total
hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®),
RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013,
Masimo introduced the Root® Patient Monitoring and Connectivity
Platform, built from the ground up to be as flexible and expandable
as possible to facilitate the addition of other Masimo and
third-party monitoring technologies; key Masimo additions include
Next Generation SedLine® Brain Function Monitoring, O3® Regional
Oximetry, and ISA™ Capnography with NomoLine® sampling lines.
Masimo’s family of continuous and spot-check monitoring Pulse
CO-Oximeters® includes devices designed for use in a variety of
clinical and non-clinical scenarios, including tetherless, wearable
technology, such as Radius-7®, Radius PPG®, and Radius VSM™,
portable devices like Rad-67®, fingertip pulse oximeters like
MightySat® Rx, and devices available for use both in the hospital
and at home, such as Rad-97® and the Masimo W1® Medical Watch.
Masimo hospital and home automation and connectivity solutions are
centered around the Masimo Hospital Automation™ platform, and
include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo
ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing
portfolio of health and wellness solutions includes Radius Tº® and
Masimo W1 Sport. Additional information about Masimo and its
products may be found at www.masimo.com. Published clinical studies
on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
References
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website. Comparative studies
include independent and objective studies which are comprised of
abstracts presented at scientific meetings and peer-reviewed
journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar.
- Estimate: Masimo data on file.
-
https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the future development, efficiency, potential performance
and adoption of the new Masimo reference platform for Wear OS (the
“Platform”), including the potential to create a world-class
smartwatch reference platform and the expectation for the platform
to be fully compatible with existing Google apps and services
created for the Wear OS platform. These forward-looking statements
are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are
difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely
from those expressed in our forward-looking statements as a result
of various risk factors, including, but not limited to: risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including the Platform, contribute to accurate,
reliable data; risks related to our belief that Masimo noninvasive
medical breakthroughs provide cost-effective solutions and unique
advantages; risks related to the assumption that the Platform will
be available for integration into future Wear OS OEM smartwatches;
risks related to the assumption that new smartwatches produced by
the OEMs adopting the Platform will have the features, components
and benefits as mentioned in this press release; risks related to
COVID-19; as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the
SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240913710494/en/
Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Oct 2023 to Oct 2024